natgillin/translations-raw huggingface dataset:
Catheter ablation for atrial fibrillation (SPAF) 
Katetrska ablacija zaradi atrijske fibrilacije (SPAF)
Effects observed in the repeated dose toxicity studies were due to the exaggerated pharmacodynamic effect of dabigatran. 
Učinki, ki so jih zasledili v študijah toksičnosti ponavljajočih odmerkov, so bili posledica prekomernega farmakodinamičnega učinka dabigatrana.
Contact your doctor immediately if you have taken too many Pradaxa capsules. 
Takoj se obrnite na svojega zdravnika, če ste vzeli preveč kapsul zdravila Pradaxa.
There was no influence on male fertility. 
Ni bilo vpliva na plodnost samcev.
It works by blocking a substance in the body which is involved in blood clot formation. 
Deluje tako, da v telesu zavira snov, ki sodeluje pri nastanku krvnega strdka.
• Strong P-gp inhibitors (see section 4.3 and 
• močni zaviralci P-gp (glejte poglavji 4.3 in
The educational pack must be available for distribution for all therapeutic indications prior to launch ) in the Member State. 
Izobraževalno gradivo za vse terapevtske indikacije mora biti pripravljeno za razdeljevanje pred prihodom na trg v posamezni državi članici.
Selective serotonin re-uptake inhibitors (SSRIs) or selective serotonin norepinephrine re-uptake inhibitors (SNRIs) 
Selektivni zaviralci ponovnega privzema serotonina (SSRI) ali selektivni zaviralci ponovnega privzema serotonina in noradrenalina (SNRI)
There is some experimental evidence to support the role of these medicinal products in reversing the anticoagulant effect of dabigatran, but data on their usefulness in clinical settings and also on the possible risk of rebound thromboembolism is very limited. 
Na voljo je nekaj eksperimentalnih podatkov, ki kažejo na možen pomen teh zdravil pri odpravi antikoagulacijskega učinka dabigatrana, zelo malo podatkov pa je o njihovi uporabnosti v klinični rabi in možnem tveganju povratne trombembolije.
The pharmacokinetics and pharmacodynamics of dabigatran etexilate administered twice daily for three consecutive days (total 6 doses) at the end of standard anticoagulant therapy were assessed in an open-label safety and tolerability study in 9 stable adolescents (12 to < 18 years). 
Farmakokinetiko in farmakodinamiko dabigatran eteksilata so pri dvakrat dnevnem dajanju tri zaporedne dni (skupno 6 odmerkov) ob koncu standardnega antikoagulacijskega zdravljenja ocenili v odprti študiji o varnosti in prenašanju pri 9 stabilnih mladostnikih (12 do < 18 let).
In patients at higher risk of bleeding or in major surgery where complete haemostasis may be required consider stopping Pradaxa 2-4 days before surgery. 
Pri bolnikih s povečanim tveganjem krvavitve in pri velikih operacijah, pri katerih je lahko potrebna popolna hemostaza, je treba presoditi o ukinitvi zdravila Pradaxa 2 do 4 dni pred operacijo.
A non-interventional study (GLORIA-AF) prospectively collected (in its second phase) safety and effectiveness data in newly diagnosed NVAF patients on dabigatran etexilate in a real-world setting. 
V neintervencijski študiji (GLORIA-AF) so bili (v drugi fazi študije) prospektivno zbrani podatki o varnosti in učinkovitosti pri na novo diagnosticiranih bolnikih z NVAF, ki so prejemali dabigatran eteksilat v realnem življenju.
In vitro interaction studies did not show any inhibition or induction of the principal isoenzymes of cytochrome P450. 
Študije interakcij in vitro niso pokazale zaviranja ali indukcije glavnih izoencimov citokroma P450.
In addition, dabigatran AUCτ,ss and Cmax,ss and the coagulation measures for dabigatran effect or the inhibition of platelet aggregation as measure of clopidogrel effect remained essentially unchanged comparing combined treatment and the respective mono-treatments. 
Poleg tega so bili dabigatranova AUCτ,ss in Cmax,ss ter merila za določanje učinka dabigatrana na strjevanje krvi ali zaviranje agregacije trombocitov kot merilo za učinek klopidogrela v glavnem nespremenjeni, ko so primerjali kombinirano zdravljenje in ustrezne monoterapije.
Active Cancer Patients (DVT/PE) 
Bolniki z aktivnim rakom (GVT/PE)
This effect was seen primarily in patients ≥ 75 years. 
Ta učinek so pretežno opazili pri 75-letnih bolnikih ali starejših.
As protein binding is low, dabigatran can be dialysed; there is limited clinical experience to demonstrate the utility of this approach in clinical studies (see section 5.2). 
Zaradi majhne vezave na beljakovine, je dabigatran mogoče dializirati, vendar je le malo kliničnih izkušenj, ki bi kazale na tovrstno uporabnost v kliničnih študijah (glejte poglavje 5.2).
Caution should be exercised when interpreting these tests. 
Izvide preskusov je treba razlagati previdno.
You may also need to talk to your doctor during treatment with Pradaxa if you experience symptoms or if you have to undergo surgery. 
Med zdravljenjem z zdravilom Pradaxa se boste morali posvetovati z zdravnikom tudi, če se bodo pojavili simptomi ali ko boste potrebovali operativno zdravljenje.
• Hepatic impairment or liver disease expected to have any impact on survival 
• jetrna okvara ali jetrna bolezen, ki bi predvidoma lahko vplivala na preživetje
if you know you have impaired kidney function, or you are suffering from dehydration (symptoms include feeling thirsty and passing reduced amounts of dark-coloured (concentrated) urine). 
• če veste, da imate okvarjeno ledvično delovanje ali ste dehidrirani (imate simptome, kot so občutek žeje ali izločanje zmanjšane količine temnega (koncentriranega) seča);
95 % confidence interval 
95-odstotni interval zaupanja
Age (years) 65 ≤ and < 75 
Starost (leta) 65≤ in < 75
SSRIs, SNRIs SSRIs and SNRIs increased the risk of bleeding in all treatment groups of a phase III clinical trial comparing dabigatran to warfarin for stroke prevention in atrial fibrillation patients (RE-LY). 
SSRI, SNRI SSRI in SNRI so povečali tveganje krvavitve pri vseh zdravljenih skupinah v III. fazi kliničnega preskušanja, v katerem so primerjali dabigatran z varfarinom glede preprečevanja možganske kapi pri bolnikih z atrijsko fibrilacijo (RE-LY).
Similar values for CrCL were found in RE-COVER II. 
V študiji RE-COVER II so bile vrednosti CrCl podobne.
Component of a multipack, can´t be sold separately. 
Enota v večkratnem pakiranju, prodaja posameznih enot ni možna.
® is an oral anticoagulant (direct thrombin inhibitor). 
® je peroralni antikoagulant (neposredni zaviralec trombina).
However, limited clinical data with another P-gp substrate (everolimus) suggest that the inhibition of P-gp with tacrolimus is weaker than that observed with strong P-gp inhibitors. 
Toda manjše število kliničnih podatkov za drugi substrat P-gp (everolimus) kaže, da je zaviralni učinek na P-gp pri takrolimusu šibkejši od opaženega pri močnih zaviralcih P-gp.
Of the 704 enrolled patients, 317 underwent atrial fibrillation ablation on uninterrupted dabigatran and 318 underwent atrial fibrillation ablation on uninterrupted warfarin. 
Od 704 vključenih bolnikov je imelo 317 bolnikov ablacijo zaradi atrijske fibrilacije ob neprekinjenem jemanju dabigatrana, 318 bolnikov pa je imelo ablacijo zaradi atrijske fibrilacije ob neprekinjenem jemanju varfarina.
Food does not affect the bioavailability of dabigatran etexilate but delays the time to peak plasma concentrations by 2 hours. 
Hrana ne vpliva na biološko uporabnost dabigatran eteksilata, toda za 2 uri podaljša čas do največje koncentracije v plazmi.
No dose adjustment is necessary (see section 5.2), but close clinical surveillance is recommended in patients with a body weight < 50 kg (see section 4.4). 
Odmerka ni potrebno prilagajati (glejte poglavje 5.2), toda priporočamo natančno klinično spremljanje pri bolnikih s telesno maso < 50 kg (glejte poglavje 4.4).
• Recent biopsy, major trauma 
• nedavna biopsija, večja poškodba
This resulted in a removal of 50 % to 60 % of dabigatran concentrations, respectively. 
Dializa je odstranila 50 % do 60 % koncentracije dabigatrana.
SPECIAL STORAGE CONDITIONS Keep the bottle tightly closed. 
POSEBNA NAVODILA ZA SHRANJEVANJE Plastenko shranjujte tesno zaprto.
Four positional isomers, 1-O, 2-O, 3-O, 4-O-acylglucuronide exist, each accounts for less than 10 % of total dabigatran in plasma. 
Poznamo štiri pozicijske izomere: 1-O-, 2-O-, 3-O- in 4-O-acilglukuronid, od katerih je delež vsakega manjši od 10 % skupnega dabigatrana v plazmi.
The half-life was independent of dose. 
Razpolovna doba ni odvisna od velikosti odmerka.
Number of patients treated with Pradaxa 
Število bolnikov zdravljenih z zdravilom Pradaxa
if you are suffering from an inflammation of the gullet or stomach. 
• če imate vnetje požiralnika ali želodca,
gMean (gCV %; range) half-life [h] 
gpovprečna (gCV%; razpon) razpolovna doba [h]
In this case Pradaxa will need to be stopped temporarily due to an increased bleeding risk during and shortly after an operation. 
V tem primeru bo zdravilo Pradaxa treba začasno prekiniti zaradi povečane nevarnosti krvavitve med operacijo in krajši čas po njej.
There was no stroke/systemic embolism/TIA (composite) event in the dabigatran etexilate arm, and one event (TIA) in the warfarin arm from the time of ablation and until 8 weeks post-ablation. 
V skupini z dabigatran eteksilatom se možganska kap/sistemska embolija/TIA (sestavljeni dogodek) ni pojavila, en dogodek (TIA) pa se je pojavil v skupini z varfarinom v času od ablacije in do 8 tednov po ablaciji.
The amount of substance cleared by dialysis is proportional to the blood flow rate up to a blood flow rate of 300 mL/min. 
Količina snovi, ki se izloči med dializo, je sorazmerna hitrosti pretoka krvi vse do hitrosti pretoka krvi 300 ml/min.
In atrial fibrillation patients females had on average 30 % higher trough and post-dose concentrations. 
Med bolniki z atrijsko fibrilacijo so imele ženske povprečno za 30 % večje koncentracije tik pred odmerkom in po odmerku.
Renal function (CrCL in mL/min) 
Ledvično delovanje (CrCl v ml/min)
Pharmacotherapeutic group: antithrombotic agents, direct thrombin inhibitors, ATC code: B01AE07. 
Farmakoterapevtska skupina: antitrombotiki, direktni zaviralci trombina, oznaka ATC: B01AE07
The anticoagulant activity of dabigatran decreased with decreasing plasma concentrations and the PK/PD relationship was not affected by the procedure. 
Antikoagulacijsko delovanje dabigatrana se je manjšalo z manjšanjem njegovih koncentracij v plazmi, na farmakokinetično/farmakodinamično razmerje pa postopek ni vplival.
There are limited efficacy and safety data for Pradaxa available in these patients and therefore they should be treated with caution. 
O učinkovitosti in varnosti zdravila Pradaxa pri teh bolnikih je malo podatkov, zato jih je treba zdraviti previdno.
With a loading dose of 300 mg or 600 mg clopidogrel, dabigatran AUCτ,ss and Cmax,ss were increased by about 30-40 % (see section 4.4) . 
Pri polnilnem odmerku klopidogrela po 300 ali 600 mg sta se dabigatranovi AUCτ,ss in Cmax,ss povečali za približno 30 do 40 % (glejte poglavje 4.4).
For the primary safety endpoint of major bleeding there was an interaction of treatment effect and age. 
Pri primarnem opazovanem dogodku, na podlagi katerega so ocenili varnost, in sicer pri veliki krvavitvi, so ugotovili interakcijo med učinkom zdravljenja in starostjo.
Elderly patients outside of the United States (≥80 years of age for all countries, ≥70 years of age for Japan) were randomly assigned to the dabigatran etexilate 110 mg dual-therapy group or the warfarin triple-therapy group. 
Starejši bolniki zunaj Združenih držav Amerike (≥ 80 let za vse države, ≥ 70 let za Japonsko) so bili naključno razporejeni v skupino z dvojno terapijo z dabigatran eteksilatom 110 mg ali trojno terapijo z varfarinom.
Pradaxa treatment does not need to be interrupted (see section 5.1). 
Zdravljenja z zdravilom Pradaxa ni potrebno prekinjati (glejte poglavje 5.1).
10 days (knee replacement surgery) or 28-35 days (hip replacement surgery) 
10 dni (pri vstavitvi umetnega kolena) ali 28-35 dni (pri vstavitvi umetnega kolka)
While certain patient subgroups are at an increased risk of major bleeding when treated with an anticoagulant, the excess bleeding risk for dabigatran is due to GI bleeding, typically seen within the first 3-6 months following initiation of Pradaxa therapy. 
Medtem ko se pri določenih podskupinah bolnikov med zdravljenjem z antikoagulantom poveča tveganje velikih krvavitev, k povečanju krvavitev pri uporabi dabigatrana prispevajo krvavitve v prebavilih, ki se značilno pojavljajo prve 3 do 6 mesecev po začetku zdravljenja z zdravilom Pradaxa.
Table 10: Number of patients studied, maximum daily dose in phase III studies Indication 
Preglednica 10: Število preiskovanih bolnikov, maksimalni dnevni odmerek v študiji faze III
In the RE-MODEL trial (knee replacement) treatment was for 6-10 days and in the RE-NOVATE trial (hip replacement) for 28-35 days. 
V preskušanju RE-MODEL (vstavitev umetnega kolena) je zdravljenje trajalo 6 do 10 dni, v preskušanju RE-NOVATE (vstavitev umetnega kolka) pa 28 do 35 dni.
Specific pharmacokinetic phase I studies with elderly subjects showed an increase of 40 to 60 % in the AUC and of more than 25 % in Cmax compared to young subjects. 
Specifične farmakokinetične študije faze I pri starejših osebah so pokazale 40- do 60-odstotno povečanje AUC in več kot 25-odstotno povečanje Cmax v primerjavi z mladimi osebami.
Table 9: Number of patients studied, maximum daily dose in phase III studies Indication 
Preglednica 9: Število preiskovanih bolnikov, maksimalni dnevni odmerek v študiji faze III
Amiodarone When Pradaxa was co-administered with a single oral dose of 600 mg amiodarone, the extent and rate of absorption of amiodarone and its active metabolite DEA were essentially unchanged. 
Amiodaron Pri sočasni uporabi zdravila Pradaxa in enkratnim peroralnim odmerkom amiodarona po 600 mg se obseg in hitrost absorpcije amiodarona in njegovega aktivnega presnovka DEA nista bistveno spremenila.
The primary endpoint was a combined endpoint of major bleeds based on ISTH definition or clinically relevant non-major bleeding event. 
Primarni opazovani dogodek je bil sestavljeni opazovani dogodek velikih krvavitev po opredelitvi ISTH ali klinično pomembna ne-velika krvavitev.
Duration of dabigatran etexilate treatment ranged from 6 to 36 months (median 534.0 days). 
Zdravljenje z dabigatran eteksilatom je trajalo 6 do 36 mesecev (srednje trajanje je bilo 534,0 dni).
In this situation Pradaxa and these medicinal products should be taken at the same time. 
V tej situaciji je treba zdravilo Pradaxa in našteta zdravila jemati hkrati.
In the RE-SONATE study, which compared dabigatran etexilate to placebo, the rate of MI was 0.1% for patients who received dabigatran etexilate and 0.2% for patients who received placebo 
V študiji RE-SONATE, v kateri so dabigatran eteksilat primerjali s placebom, je bila stopnja pojavnosti miokardnega infarkta 0,1 % pri bolnikih, ki so jemali dabigatran eteksilat, in 0,2 % pri tistih, ki so jemali placebo.
Dabigatran is a potent, competitive, reversible direct thrombin inhibitor and is the main active principle in plasma. 
Dabigatran je močen, kompetitiven, reverzibilen direktni zaviralec trombina in glavna učinkovina v plazmi.
Pradaxa ® Information for Patients About your treatment 
Informacije za bolnike O vašem zdravljenju
You can continue to take Pradaxa if your heart beat needs to be restored to normal by a procedure called cardioversion. 
Zdravilo Pradaxa lahko jemljete še naprej, četudi je bilo vaš srčni utrip potrebno normalizirati s postopkom, ki se mu reče kardioverzija.
Patients with elevated liver enzymes > 2 ULN were excluded in controlled clinical trials investigating the VTE prevention following elective hip or knee replacement surgery. 
Bolnike s povečanimi jetrnimi encimi na > 2 ULN so izključili iz nadzorovanih kliničnih preskušanj, v katerih so proučevali preprečevanje VTE po operativni vstavitvi umetnega kolka ali kolena.
The RE-LY extension study (RELY-ABLE) provided additional safety information for a cohort of patients which continued the same dose of dabigatran etexilate as assigned in the RE-LY trial. 
V podaljšku študije RE-LY (RELY-ABLE) so pridobili dodatne podatke o varnosti v kohorti bolnikov, ki so nadaljevali z jemanjem enakega odmerka dabigatran eteksilata, kot je bil predpisan v študiji RE-LY.
An increased risk was seen in the elderly (≥ 75 years) for the 150 mg twice daily dose regimen. 
Povečano tveganje so opazili pri starejših (≥ 75 let) pri odmerjanju 150 mg dvakrat na dan.
Patients who underwent Percutaneous coronary intervention (PCI) with stenting 
Bolniki, ki so imeli perkutano koronarno intervencijo (PKI) z vstavitvijo žilne opornice
Results of both studies showed that the antithrombotic effect of Pradaxa 220 mg and 150 mg were statistically non-inferior to that of enoxaparin on total VTE and all-cause mortality. 
Izsledki obeh študij so pokazali, da antitrombotični učinek zdravila Pradaxa v odmerku 220 mg in 150 mg ni statistično manjši od učinka enoksaparina, če upoštevamo skupno pojavnost trombemboličnih dogodkov in umrljivost iz vseh vzrokov.
Haemorrhagic complications may present as weakness, paleness, dizziness, headache or unexplained swelling, dyspnoea, and unexplained shock. 
Zapleti s krvavitvami se lahko pokažejo kot oslabelost, bledica, omotica, glavobol ali nepojasnjeno otekanje, dispneja in nepojasnjen šok.
Life-threatening bleeding was reported in 0.46 per 100 patient-years, intracranial haemorrhage in 0.17 per 100 patient-years and gastrointestinal bleeding in 0.60 per 100 patient-years. 
O življenjsko nevarnih krvavitvah so poročali pri 0,46 na 100 bolnik-let, o intrakranialni krvavitvi pri 0,17 na 100 bolnikov-let in o krvavitvi v prebavilih pri 0,60 na 100 bolnik-let.
When taking a hard capsule out of the bottle, the following instructions should be observed: 
Ko boste jemali trde kapsule iz plastenke, morate upoštevati naslednja navodila:
Dosing should be reduced as indicated in table 1 (see also sections 4.4 and 4.5). 
Odmerek je treba zmanjšati, kot je navedeno v preglednici 1 (glejte tudi poglavji 4.4 in 4.5).
In a study performed with 24 healthy subjects, when Pradaxa was co-administered with digoxin, no changes on digoxin and no clinically relevant changes on dabigatran exposure have been observed. 
V študiji na 24 zdravih osebah, kjer so zdravilo Pradaxa dajali sočasno z digoksinom, niso zasledili spremenjene izpostavljenosti digoksinu ali klinično pomembno spremenjene izpostavljenosti dabigatranu.
Substances influencing gastric pH 
Snovi, ki vplivajo na želodčni pH
if you have problems with reflux of gastric juice into the gullet. 
• če imate težave z zatekanjem želodčnega soka v požiralnik,
Pre-dosing of the probe inducer rifampicin at a dose of 600 mg once daily for 7 days decreased total dabigatran peak and total exposure by 65.5 % and 67 %, respectively. 
Pri predhodnem dajanju preizkušanega induktorja rifampicina v odmerkih po 600 mg enkrat na dan, 7 dni, sta se skupna najvišja koncentracija dabigatrana in izpostavljenost zmanjšala za 65,5 oziroma 67 %.
Active substance exposure in the primary VTE prevention studies was about 40 % to 50 % higher in female patients and no dose adjustment is recommended. 
Izpostavljenost zdravilni učinkovini v študijah o preprečevanju VTE je bila približno 40 do 50 % večja pri bolnicah, prilagajanja odmerka pa ne priporočajo.
Hepatic impairment or liver disease expected to have any impact on survival is contraindicated (see section 4.3). 
Jetrna okvara ali jetrna bolezen, ki bi lahko vplivala na preživetje, je kontraindicirana (glejte poglavje 4.3).
No clinically relevant inter-ethnic differences among Caucasian, African-American, Hispanic, Japanese or Chinese patients were observed regarding dabigatran pharmacokinetics and pharmacodynamics. 
Pri belcih, Afroameričanih, hispanih, Japoncih in Kitajcih niso ugotovili medetničnih razlik v dabigatranovi farmakokinetiki in farmakodinamiki.
if you are suffering from an infection of the heart (bacterial endocarditis). 
• če imate bakterijski endokarditis (okužbo notranje srčne ovojnice),
Test (trough value) dTT [ng/mL] 
Preskus (najnižja vrednost) dTT [ng/ml]
The efficacy and safety have not been established for DVT/PE patients with active cancer. 
Učinkovitost in varnost zdravila pri bolnikih z GVT ali PE in aktivnim rakom še nista raziskani.
Patients at high surgical mortality risk and with intrinsic risk factors for thromboembolic events 
Bolniki z velikim tveganjem umrljivosti med operacijo in intrinzičnimi dejavniki tveganja za trombembolične dogodke
Both dose strengths of Pradaxa had also a statistically significant lower total bleed rate. 
Pri obeh jakostih zdravila Pradaxa je bil statistično značilno manjši tudi odstotek vseh krvavitev.
® may need to be stopped in advance of surgical or other invasive procedures. 
® bo morda treba ukiniti pred operacijami in drugimi invazivnimi postopki.
• Renal function should be assessed by calculating the creatinine clearance (CrCL) prior to initiation of treatment with Pradaxa to exclude patients with severe renal impairment (i.e. CrCL < 30 mL/min) (see sections 4.3, 4.4 and 5.2). 
• Ledvično delovanje je treba na podlagi izračuna kreatininskega očistka (CrCl) oceniti pred začetkom zdravljenja z zdravilom Pradaxa, da bi lahko izključili bolnike s hudo ledvično okvaro (tj. CrCl < 30 ml/min) (glejte poglavja 4.3, 4.4 in 5.2).
Blister and bottle 3 years 
Pretisni omot in plastenka 3 leta
RELY-ABLE (Long term multi-center extension of dabigatran treatment in patients with atrial fibrillation who completed the RE-LY trial) 
Študija RELY-ABLE (dolgotrajen, multicentrični podaljšek zdravljenja z dabigatranom pri bolnikih z atrijsko fibrilacijo po končani študiji RE-LY)
Pharmacodynamic and kinetic factors 
Farmakodinamični in kinetični dejavniki
Since dabigatran is excreted predominantly by the renal route adequate diuresis must be maintained. 
Ker se dabigatran pretežno izloča preko ledvic, moramo vzdrževati ustrezno diurezo.
As this patient alert card contains important information about your treatment, please carry this card with you at all times to inform healthcare professionals about your intake of Pradaxa 
Opozorilna kartica za bolnika vsebuje pomembne podatke o vašem zdravljenju, zato jo imejte vedno pri sebi, tako boste lahko zdravstvenim delavcem pokazali, da jemljete zdravilo Pradaxa
• Details of populations potentially at higher risk of bleeding 
• Podroben opis populacij, pri katerih je lahko povečano tveganje krvavitev
All patients received an initial oral dose of 1.71 (± 10%) mg/kg of dabigatran etexilate (80 % of the adult dose of 150 mg/70 kg adjusted for the patient's weight). 
Vsi bolniki so dobili začetni peroralni odmerek po 1,71 (± 10 %) mg/kg dabigatran eteksilata (80 % odmerka za odrasle 150 mg/70 kg, prilagojeno bolnikovi telesni masi).
None of these diseases showed an impact on the effects of dabigatran on VTE-prevention or bleeding rates. 
Nobena od naštetih bolezni ni vplivala na učinkovitost dabigatrana pri preprečevanju venskih trombemboličnih dogodkov ali stopnjo krvavitve.
The median CrCL in the RE-COVER study was 100.4 mL/min. 
Mediana CrCl je bila v študiji RE-COVER 100,4 ml/min.
• In case of major bleeding events, Pradaxa ® must be stopped immediately. 
• Pri večjih krvavitvah je treba zdravilo Pradaxa ® nemudoma ukiniti.
Clearance of dabigatran in patients with renal insufficiency may take longer (see section 5.2). 
Pri bolnikih z ledvično insuficienco se lahko podaljša dabigatranov očistek (glejte poglavje 5.2).
Clearance of dabigatran by haemodialysis was investigated in 7 patients with end-stage renal disease (ESRD) without atrial fibrillation. 
Očistek dabigatrana med hemodializo so proučevali pri 7 bolnikih s končnim stadijem ledvične bolezni in brez atrijske fibrilacije.
Prevention of blood clot formation after knee or hip replacement surgery Continue with your remaining daily doses of Pradaxa at the same time of the next day. 
Preprečevanje nastajanja krvnih strdkov po operativni vstavitvi umetnega kolena ali kolka Nadaljujte s preostalim dnevnim odmerkom zdravila Pradaxa ob istem času naslednjega dne.